Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Cambridge Cognition Holdings ( (GB:COG) ) has provided an update.
Cambridge Cognition has submitted a Letter of Intent to the FDA to develop a digital tool for assessing cognitive impairment in schizophrenia patients, potentially improving clinical trial efficiency and treatment development. This initiative highlights the company’s strategic focus on addressing cognitive symptoms in schizophrenia, which significantly impact patients’ daily lives and remain untreated.
More about Cambridge Cognition Holdings
Cambridge Cognition is a brain health software group specializing in digital health products that advance brain health research and treatment. The company offers products like CANTAB® assessments for cognitive function, an eCOA platform for data capture, rater training services, and quality assurance tools to enhance clinical trial outcomes and efficiency in healthcare and pharmaceuticals.
YTD Price Performance: 21.33%
Average Trading Volume: 61,978
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £19.05M
For a thorough assessment of COG stock, go to TipRanks’ Stock Analysis page.
